Enumera Molecular
Enumera Molecular: Innovating low-cost, rapid clinical testing with scalable life science tools.
Founded
2022Enumera Molecular: Innovating low-cost, rapid clinical testing with scalable life science tools.
Enumera Molecular, founded in Ann Arbor, MI, is a life science tools company dedicated to transforming clinical molecular testing. Their core mission is to develop scalable biomolecule assessment platforms that enable low-cost, rapid clinical liquid biopsy tests. Enumera Molecular offers the EnumeraPlex platform, a single-molecule counting technology designed to simplify complex, high-analyte molecular testing. This platform provides high-performance pan-omic detection without PCR bias and eliminates the need for bioinformatics analysis, making it accessible and efficient for laboratory use.
Notable figures associated with Enumera Molecular include key scientists and industry experts who have contributed to the development of their innovative technologies. The company has attracted significant investment from venture capital firms specializing in life sciences. Enumera Molecular's achievements include the successful deployment of their EnumeraPlex platform in various clinical settings, demonstrating its potential to revolutionize molecular diagnostics. Their impact lies in making advanced molecular testing more accessible, cost-effective, and user-friendly, thereby enhancing the precision and speed of clinical diagnostics.
Companies similar to Enumera Molecular include Molecular Loop, Signatur Biosciences, Nanopath and Prompt Diagnostics.
Enumera Molecular was founded in 2022.
Enumera Molecular's headquarters is located in Ann Arbor, MI, US.
Enumera Molecular's most recent funding round was for $12.5M (USD) in May 2022.
As of May 5, 2022, Enumera Molecular has raised a total of $12.5M (USD).
Enumera Molecular has 23 employees as of Feb 5, 2024.
Nanopath
nanopathdx.com
